{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T02:43:11Z","timestamp":1794278591328,"version":"4.9.0"},"reference-count":122,"publisher":"European Respiratory Society (ERS)","issue":"156","license":[{"start":{"date-parts":[[2020,6,16]],"date-time":"2020-06-16T00:00:00Z","timestamp":1592265600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["Eur Respir Rev"],"accepted":{"date-parts":[[2020,3,9]]},"published-print":{"date-parts":[[2020,6,30]]},"abstract":"<jats:p>Cystic fibrosis transmembrane conductance regulator (CFTR) is an ion transporter that regulates mucus hydration, viscosity and acidity of the airway epithelial surface. Genetic defects in<jats:italic>CFTR<\/jats:italic>impair regulation of mucus homeostasis, causing severe defects of mucociliary clearance as seen in cystic fibrosis. Recent work has established that CFTR dysfunction can be acquired in chronic obstructive pulmonary disease (COPD) and may also contribute to other diseases that share clinical features of cystic fibrosis, such as asthma, allergic bronchopulmonary aspergillosis and bronchiectasis. Protean causes of CFTR dysfunction have been identified including cigarette smoke exposure, toxic metals and downstream effects of neutrophil activation pathways. Recently, CFTR modulators, small molecule agents that potentiate CFTR or restore diminished protein levels at the cell surface, have been successfully developed for various<jats:italic>CFTR<\/jats:italic>gene defects, prompting interest in their use to treat diseases of acquired dysfunction. The spectrum of CFTR dysfunction, strategies for CFTR modulation, and candidate diseases for CFTR modulation beyond cystic fibrosis will be reviewed in this manuscript.<\/jats:p>","DOI":"10.1183\/16000617.0068-2019","type":"journal-article","created":{"date-parts":[[2020,6,17]],"date-time":"2020-06-17T11:05:14Z","timestamp":1592391914000},"page":"190068","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":45,"title":["CFTR targeted therapies: recent advances in cystic fibrosis and possibilities in other diseases of the airways"],"prefix":"10.1183","volume":"29","author":[{"given":"Sheylan D.","family":"Patel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taylor R.","family":"Bono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9045-0133","authenticated-orcid":false,"given":"Steven M.","family":"Rowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George M.","family":"Solomon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2020,6,16]]},"reference":[{"key":"2024102403445546000_29.156.190068.1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60327-5"},{"key":"2024102403445546000_29.156.190068.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0910061"},{"key":"2024102403445546000_29.156.190068.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMe020070"},{"key":"2024102403445546000_29.156.190068.4","doi-asserted-by":"crossref","unstructured":"Redente EF , Jakubzick CV , Martin TR , et al. Innate Immunity. In: Broaddus VC , Mason RJ , Ernst JD , et al. eds. Murray and Nadel's Textbook of Respiratory Medicine. Philadelphia, Elsevier, 2016; pp. 184\u2013205.","DOI":"10.1016\/B978-1-4557-3383-5.00012-9"},{"key":"2024102403445546000_29.156.190068.5","doi-asserted-by":"crossref","first-page":"e97199","DOI":"10.1172\/jci.insight.97199","article-title":"Development of an airway mucus defect in the cystic fibrosis rat","volume":"3","author":"Birket","year":"2018","journal-title":"JCI Insight"},{"key":"2024102403445546000_29.156.190068.6","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.23247"},{"key":"2024102403445546000_29.156.190068.7","doi-asserted-by":"publisher","DOI":"10.1038\/srep36016"},{"key":"2024102403445546000_29.156.190068.8","doi-asserted-by":"publisher","DOI":"10.1038\/nature11130"},{"key":"2024102403445546000_29.156.190068.9","doi-asserted-by":"publisher","DOI":"10.1152\/ajplung.00094.2011"},{"key":"2024102403445546000_29.156.190068.10","doi-asserted-by":"publisher","DOI":"10.1007\/s00441-016-2562-z"},{"key":"2024102403445546000_29.156.190068.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2015.06.002"},{"key":"2024102403445546000_29.156.190068.12","doi-asserted-by":"publisher","DOI":"10.1016\/S1569-1993(11)60021-0"},{"key":"2024102403445546000_29.156.190068.13","doi-asserted-by":"crossref","first-page":"L909","DOI":"10.1152\/ajplung.00556.2017","article-title":"Seeing cilia: imaging modalities for ciliary motion and clinical connections","volume":"314","author":"Peabody","year":"2018","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"2024102403445546000_29.156.190068.14","doi-asserted-by":"publisher","DOI":"10.1165\/rcmb.2013-0499MA"},{"key":"2024102403445546000_29.156.190068.15","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0606428103"},{"key":"2024102403445546000_29.156.190068.16","doi-asserted-by":"publisher","DOI":"10.1038\/nm1028"},{"key":"2024102403445546000_29.156.190068.17","unstructured":"Clinical and Functional TRanslation of CFTR (CFTR2) . http:\/\/cftr2.org Date last accessed: 1 March 2020; date last updated: 1 March 2020."},{"key":"2024102403445546000_29.156.190068.18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra043184"},{"key":"2024102403445546000_29.156.190068.19","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s12967-017-1193-9","article-title":"Cystic fibrosis: current therapeutic targets and future approaches","volume":"15","author":"Rafeeq","year":"2017","journal-title":"J Transl Med"},{"key":"2024102403445546000_29.156.190068.20","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200505-840OE"},{"key":"2024102403445546000_29.156.190068.21","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.23240"},{"key":"2024102403445546000_29.156.190068.22","doi-asserted-by":"publisher","DOI":"10.1038\/nrg3849"},{"key":"2024102403445546000_29.156.190068.23","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0800254105"},{"key":"2024102403445546000_29.156.190068.24","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M508131200"},{"key":"2024102403445546000_29.156.190068.25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2008.03.009"},{"key":"2024102403445546000_29.156.190068.26","doi-asserted-by":"publisher","DOI":"10.1172\/JCI110917"},{"key":"2024102403445546000_29.156.190068.27","doi-asserted-by":"publisher","DOI":"10.1378\/chest.13-0274"},{"key":"2024102403445546000_29.156.190068.28","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200508-1330OC"},{"key":"2024102403445546000_29.156.190068.29","doi-asserted-by":"publisher","DOI":"10.1152\/ajplung.00376.2004"},{"key":"2024102403445546000_29.156.190068.30","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.164.supplement_2.2106067"},{"key":"2024102403445546000_29.156.190068.31","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0039809"},{"key":"2024102403445546000_29.156.190068.32","doi-asserted-by":"publisher","DOI":"10.1186\/1465-9921-15-25"},{"key":"2024102403445546000_29.156.190068.33","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201304-0733OC"},{"key":"2024102403445546000_29.156.190068.34","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-016-2391-y"},{"key":"2024102403445546000_29.156.190068.35","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201205-0875OC"},{"key":"2024102403445546000_29.156.190068.36","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.2003755"},{"key":"2024102403445546000_29.156.190068.37","doi-asserted-by":"publisher","DOI":"10.1126\/science.1223012"},{"key":"2024102403445546000_29.156.190068.38","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/01.JAA.0000515540.36581.92","article-title":"Keep them breathing: Cystic fibrosis pathophysiology, diagnosis, and treatment","volume":"30","author":"Brown","year":"2017","journal-title":"JAAPA"},{"key":"2024102403445546000_29.156.190068.39","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200812-1845PP"},{"key":"2024102403445546000_29.156.190068.40","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0701833"},{"key":"2024102403445546000_29.156.190068.41","doi-asserted-by":"publisher","DOI":"10.1513\/pats.200703-042BR"},{"key":"2024102403445546000_29.156.190068.42","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0904709106"},{"key":"2024102403445546000_29.156.190068.43","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1105185"},{"key":"2024102403445546000_29.156.190068.44","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2011.12.005"},{"key":"2024102403445546000_29.156.190068.45","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2014.09.005"},{"key":"2024102403445546000_29.156.190068.46","unstructured":"FDA expands approved use of Kalydeco to treat additional mutations of cystic fibrosis [press release]. US Food and Drug Administration, 2017. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-expands-approved-use-kalydeco-treat-additional-mutations-cystic-fibrosis Date last accessed: 15 February 2020; date last updated: 15 February 2020."},{"key":"2024102403445546000_29.156.190068.47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1513\/AnnalsATS.201708-668PS","article-title":"The U.S. Food and Drug Administration's experience with ivacaftor in cystic fibrosis. establishing efficacy using in vitro data in lieu of a clinical trial","volume":"15","author":"Durmowicz","year":"2018","journal-title":"Ann Am Thorac Soc"},{"key":"2024102403445546000_29.156.190068.48","doi-asserted-by":"publisher","DOI":"10.1152\/ajplung.00169.2005"},{"key":"2024102403445546000_29.156.190068.49","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S2213-2600(14)70132-8","article-title":"A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial","volume":"2","author":"Boyle","year":"2014","journal-title":"Lancet Respir Med"},{"key":"2024102403445546000_29.156.190068.50","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1510466"},{"key":"2024102403445546000_29.156.190068.51","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709846"},{"key":"2024102403445546000_29.156.190068.52","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709847"},{"key":"2024102403445546000_29.156.190068.53","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32597-8"},{"key":"2024102403445546000_29.156.190068.54","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1908639"},{"key":"2024102403445546000_29.156.190068.55","doi-asserted-by":"publisher","DOI":"10.1513\/pats.200703-043BR"},{"issue":"Suppl. 62","key":"2024102403445546000_29.156.190068.56","first-page":"PA617","article-title":"A randomized, placebo controlled 4-week study in COPD of QBW251, a potentiator of the cystic fibrosis transmembrane conductance regulator (CFTR) protein","volume":"52","author":"Rowe","year":"2018","journal-title":"Eur Repir J"},{"key":"2024102403445546000_29.156.190068.57","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.ccm.2015.11.003","article-title":"Acquired cystic fibrosis transmembrane conductance regulator dysfunction in chronic bronchitis and other diseases of mucus clearance","volume":"37","author":"Raju","year":"2016","journal-title":"Clin Chest Med"},{"key":"2024102403445546000_29.156.190068.58","doi-asserted-by":"publisher","DOI":"10.1093\/toxsci\/kfq101"},{"key":"2024102403445546000_29.156.190068.59","doi-asserted-by":"crossref","first-page":"e123467","DOI":"10.1172\/jci.insight.123467","article-title":"Influenza-mediated reduction of lung epithelial ion channel activity leads to dysregulated pulmonary fluid homeostasis","volume":"3","author":"Brand","year":"2018","journal-title":"JCI Insight"},{"key":"2024102403445546000_29.156.190068.60","doi-asserted-by":"publisher","DOI":"10.1096\/fj.11-192377"},{"key":"2024102403445546000_29.156.190068.61","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200509-1377OC"},{"key":"2024102403445546000_29.156.190068.62","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.201509-601KV"},{"key":"2024102403445546000_29.156.190068.63","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.95.9.4882"},{"key":"2024102403445546000_29.156.190068.64","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0038038"},{"key":"2024102403445546000_29.156.190068.65","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1165\/rcmb.2016-0226OC","article-title":"The cystic fibrosis transmembrane conductance regulator potentiator ivacaftor augments mucociliary clearance abrogating cystic fibrosis transmembrane conductance regulator inhibition by cigarette smoke","volume":"56","author":"Raju","year":"2017","journal-title":"Am J Respir Cell Mol Biol"},{"key":"2024102403445546000_29.156.190068.66","doi-asserted-by":"publisher","DOI":"10.1152\/ajplung.00163.2013"},{"key":"2024102403445546000_29.156.190068.67","doi-asserted-by":"publisher","DOI":"10.1165\/rcmb.2017-0432OC"},{"key":"2024102403445546000_29.156.190068.68","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)66456-2"},{"key":"2024102403445546000_29.156.190068.69","doi-asserted-by":"publisher","DOI":"10.1016\/S0013-9351(89)80065-9"},{"key":"2024102403445546000_29.156.190068.70","doi-asserted-by":"publisher","DOI":"10.1378\/chest.12-0595"},{"key":"2024102403445546000_29.156.190068.71","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1016\/0140-6736(90)91216-W","article-title":"Abnormal distribution of cystic fibrosis delta F508 allele in adults with chronic bronchial hypersecretion","volume":"335","author":"Dumur","year":"1990","journal-title":"Lancet"},{"key":"2024102403445546000_29.156.190068.72","doi-asserted-by":"publisher","DOI":"10.1007\/BF01649427"},{"key":"2024102403445546000_29.156.190068.73","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/0140-6736(93)92046-V","article-title":"Sweat chloride and delta F508 mutation in chronic bronchitis or bronchiectasis","volume":"342","author":"Gervais","year":"1993","journal-title":"Lancet"},{"key":"2024102403445546000_29.156.190068.74","doi-asserted-by":"publisher","DOI":"10.1186\/1465-9921-15-18"},{"key":"2024102403445546000_29.156.190068.75","doi-asserted-by":"publisher","DOI":"10.1007\/s004390100467"},{"key":"2024102403445546000_29.156.190068.76","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1007\/BF00209408","article-title":"Common CFTR mutations are not likely to predispose to chronic bronchitis in northern Germany","volume":"95","author":"Artlich","year":"1995","journal-title":"Hum Genet"},{"issue":"Suppl. 1","key":"2024102403445546000_29.156.190068.77","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1159\/000337801","article-title":"Neutrophilic inflammation in severe asthma","volume":"158","author":"Nakagome","year":"2012","journal-title":"Int Arch Allergy Immunol"},{"key":"2024102403445546000_29.156.190068.78","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1155\/2012\/546702","article-title":"Cystic fibrosis transmembrane conductance regulator gene abnormalities in patients with asthma and recurrent neutrophilic bronchitis","volume":"19","author":"Goodwin","year":"2012","journal-title":"Can Respir J"},{"key":"2024102403445546000_29.156.190068.79","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ccm.2018.10.014","article-title":"Proinflammatory pathways in the pathogenesis of asthma","volume":"40","author":"Peebles","year":"2019","journal-title":"Clin Chest Med"},{"key":"2024102403445546000_29.156.190068.80","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.159.5.9805028"},{"key":"2024102403445546000_29.156.190068.81","doi-asserted-by":"publisher","DOI":"10.1186\/1465-9921-7-135"},{"key":"2024102403445546000_29.156.190068.82","doi-asserted-by":"publisher","DOI":"10.1378\/chest.09-3058"},{"key":"2024102403445546000_29.156.190068.83","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.jcf.2015.10.011","article-title":"Non-allergic asthma as a CFTR-related disorder","volume":"15","author":"Schulz","year":"2016","journal-title":"J Cyst Fibros"},{"key":"2024102403445546000_29.156.190068.84","doi-asserted-by":"publisher","DOI":"10.1165\/ajrcmb.13.6.7576713"},{"key":"2024102403445546000_29.156.190068.85","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/S0140-6736(05)61538-3","article-title":"DeltaF508 heterozygosity and asthma","volume":"352","author":"Lowenfels","year":"1998","journal-title":"Lancet"},{"key":"2024102403445546000_29.156.190068.86","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(97)11419-2"},{"key":"2024102403445546000_29.156.190068.87","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/S0140-6736(05)61539-5","article-title":"DeltaF508 heterozygosity and asthma. EGEA Co-operative Group","volume":"352","author":"Kauffmann","year":"1998","journal-title":"Lancet"},{"key":"2024102403445546000_29.156.190068.88","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1038\/nm1095-978b","article-title":"Heterozygotes for the delta F508 cystic fibrosis allele are not protected against bronchial asthma","volume":"1","author":"Mennie","year":"1995","journal-title":"Nat Med"},{"key":"2024102403445546000_29.156.190068.89","doi-asserted-by":"publisher","DOI":"10.1038\/nm0795-703"},{"key":"2024102403445546000_29.156.190068.90","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1098-1004(199912)14:6<510::AID-HUMU10>3.0.CO;2-O"},{"key":"2024102403445546000_29.156.190068.91","doi-asserted-by":"publisher","DOI":"10.1111\/j.1439-0507.2011.02130.x"},{"key":"2024102403445546000_29.156.190068.92","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2010.145862"},{"key":"2024102403445546000_29.156.190068.93","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.ccm.2012.03.004","article-title":"The initial evaluation of adults with bronchiectasis","volume":"33","author":"Metersky","year":"2012","journal-title":"Clin Chest Med"},{"key":"2024102403445546000_29.156.190068.94","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccm.2007.02.014"},{"issue":"Suppl. 2","key":"2024102403445546000_29.156.190068.95","first-page":"S123","article-title":"Neutrophil Fates in Bronchiectasis and Alpha-1 Antitrypsin Deficiency","volume":"13","author":"Russell","year":"2016","journal-title":"Ann Am Thorac Soc"},{"key":"2024102403445546000_29.156.190068.96","unstructured":"Murray JF , Nadel JA , Broaddus VC , et al. Murray & Nadel's textbook of respiratory medicine. Philadelphia, Elsevier Saunders, 2016; pp. 853\u2013876."},{"key":"2024102403445546000_29.156.190068.97","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2003.020263"},{"key":"2024102403445546000_29.156.190068.98","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2015.02.012"},{"key":"2024102403445546000_29.156.190068.99","doi-asserted-by":"publisher","DOI":"10.1007\/s004390050897"},{"key":"2024102403445546000_29.156.190068.100","doi-asserted-by":"publisher","DOI":"10.1111\/j.0009-9163.2004.00265.x"},{"key":"2024102403445546000_29.156.190068.101","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1159\/000484750","article-title":"CFTR gene mutations in adults with disseminated bronchiectasis","volume":"5","author":"Girodon","year":"1997","journal-title":"Eur J Hum Genet"},{"key":"2024102403445546000_29.156.190068.102","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200909-1434OC"},{"key":"2024102403445546000_29.156.190068.103","doi-asserted-by":"publisher","DOI":"10.1172\/JCI639"},{"key":"2024102403445546000_29.156.190068.104","doi-asserted-by":"publisher","DOI":"10.1113\/jphysiol.2006.126086"},{"key":"2024102403445546000_29.156.190068.105","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2008.717"},{"key":"2024102403445546000_29.156.190068.106","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0805800"},{"key":"2024102403445546000_29.156.190068.107","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa063070"},{"key":"2024102403445546000_29.156.190068.108","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00160007"},{"key":"2024102403445546000_29.156.190068.109","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00060806"},{"key":"2024102403445546000_29.156.190068.110","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-93-3-391"},{"key":"2024102403445546000_29.156.190068.111","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(81)91970-X"},{"key":"2024102403445546000_29.156.190068.112","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60869-7"},{"key":"2024102403445546000_29.156.190068.113","first-page":"CD001287","article-title":"Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease","volume":"3","author":"Poole","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"2024102403445546000_29.156.190068.114","doi-asserted-by":"publisher","DOI":"10.1165\/rcmb.2013-0228OC"},{"key":"2024102403445546000_29.156.190068.115","doi-asserted-by":"publisher","DOI":"10.1186\/1465-9921-12-18"},{"key":"2024102403445546000_29.156.190068.116","doi-asserted-by":"publisher","DOI":"10.1152\/ajplung.00395.2014"},{"key":"2024102403445546000_29.156.190068.117","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1186\/s12931-017-0656-0","article-title":"Roflumilast reverses CFTR-mediated ion transport dysfunction in cigarette smoke-exposed mice","volume":"18","author":"Raju","year":"2017","journal-title":"Respir Res"},{"key":"2024102403445546000_29.156.190068.118","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s12931-015-0179-5","article-title":"Roflumilast improves corticosteroid resistance COPD bronchial epithelial cells stimulated with toll like receptor 3 agonist","volume":"16","author":"Milara","year":"2015","journal-title":"Respir Res"},{"key":"2024102403445546000_29.156.190068.119","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/S2213-2600(18)30331-X","article-title":"Anti-inflammatory effects of roflumilast in chronic obstructive pulmonary disease (ROBERT): a 16-week, randomised, placebo-controlled trial","volume":"6","author":"Rabe","year":"2018","journal-title":"Lancet Respir Med"},{"key":"2024102403445546000_29.156.190068.120","doi-asserted-by":"crossref","first-page":"e32","DOI":"10.1016\/S2213-2600(16)30047-9","article-title":"Pilot evaluation of ivacaftor for chronic bronchitis","volume":"4","author":"Solomon","year":"2016","journal-title":"Lancet Respir Med"},{"key":"2024102403445546000_29.156.190068.121","unstructured":"The Topic Trial - Study to Determine the Safety and Efficacy of Ivacaftor. https:\/\/ClinicalTrials.gov\/show\/NCT03085485 Date last accessed: 1 March 2020; date last updated: 1 March 2020."},{"key":"2024102403445546000_29.156.190068.122","unstructured":"Clearing Lungs With ENaC Inhibition in Primary Ciliary Dyskinesia. https:\/\/ClinicalTrials.gov\/show\/NCT02871778 Date last accessed: 1 March 2020; date last updated: 1 March 2020."}],"container-title":["European Respiratory Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/16000617.0068-2019","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T05:01:36Z","timestamp":1740373296000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/16000617.0068-2019"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,16]]},"references-count":122,"journal-issue":{"issue":"156","published-online":{"date-parts":[[2020,6,16]]},"published-print":{"date-parts":[[2020,6,30]]}},"alternative-id":["10.1183\/16000617.0068-2019"],"URL":"https:\/\/doi.org\/10.1183\/16000617.0068-2019","relation":{},"ISSN":["0905-9180","1600-0617"],"issn-type":[{"value":"0905-9180","type":"print"},{"value":"1600-0617","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,16]]}}}